| Identification | Back Directory | [Name]
NL 1 | [CAS]
188532-26-5 | [Synonyms]
NL 1
2,4-Thiazolidinedione, 5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]- | [Molecular Formula]
C18H25NO3S | [MDL Number]
MFCD32671359 | [MOL File]
188532-26-5.mol | [Molecular Weight]
335.46 |
| Chemical Properties | Back Directory | [Boiling point ]
446.5±40.0 °C(Predicted) | [density ]
1.167±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
DMSO: 250 mg/mL (745.25 mM) | [form ]
Solid | [pka]
6.34±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC50s of 47.35 μM and 56.26 μM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway[1]. | [in vivo]
NL-1 (10 mg/kg; intraperitoneal injection; daily; for 5 days; female NSG mice) treatment shows antileukemic activity in an in vivo mouse ALL model[1]. | Animal Model: | 10 female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (6-8 month old) injected with TOM-1 ALL cells[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection; daily; for 5 days | | Result: | Showed antileukemic activity in an in vivo mouse ALL model.
|
| [References]
[1] Geldenhuys WJ, et al. The MitoNEET Ligand NL-1 Mediates Antileukemic Activity in Drug-Resistant B-Cell Acute Lymphoblastic Leukemia. J Pharmacol Exp Ther. 2019 Jul;370(1):25-34. DOI:10.1124/jpet.118.255984 |
|
|